



## **IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference**

August 30, 2021

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, President, Chief Executive Officer and co-founder of IN8bio, will present at the NewYorkBIO Virtual Breakfast Series and the virtual H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference.

Event: NewYorkBIO Virtual Breakfast Series

Date: August 31

Presentation: Webinar – Fireside Chat

Time: August 31<sup>st</sup> at 9 am EDT

Link: <https://bit.ly/3DkM2Rn>

Event: H.C. Wainwright 23rd Annual Global Investment Conference

Date: September 13-14<sup>th</sup>

Presentation: Video presentation

Time: Available starting September 13<sup>th</sup> at 7 am EDT

Link: <https://bit.ly/3jIRaMQ>

Webcasts of the presentations can also be accessed through the Events & Presentations section of the Company's website at <https://investors.in8bio.com/news-events/events-presentations>. The H.C Wainwright presentation will be available for approximately 90 days following the release of the video presentation.

### **About IN8bio**

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.

For more information about IN8bio and its programs, please visit [www.IN8bio.com](http://www.IN8bio.com).

### **Company Contact:**

IN8bio, Inc.

Kate Rochlin, Ph.D.

+1 646.600.6GDT (6438)

[info@IN8bio.com](mailto:info@IN8bio.com)

### **Investors:**

Solebury Trout

Nicholas Colangelo

+ 1 646.378.2929

[ncolangelo@troutgroup.com](mailto:ncolangelo@troutgroup.com)

### **Media:**

Burns McClellan, Inc.

Robert Flamm, Ph.D. / Harrison Wong

+1 212.213.0006 - ext. 364 / 316

[rflamm@burnsmc.com](mailto:rflamm@burnsmc.com) / [hwong@burnsmc.com](mailto:hwong@burnsmc.com)